HUTCHMED (China) Limited (H7T1) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HUTCHMED (China) Limited (H7T1) has a cash flow conversion efficiency ratio of -0.140x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-89.37 Million ≈ $-104.48 Million USD) by net assets (€636.87 Million ≈ $744.57 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see HUTCHMED (China) Limited stock valuation for the company's overall valuation and market capitalisation.
HUTCHMED (China) Limited - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how HUTCHMED (China) Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
HUTCHMED (China) Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HUTCHMED (China) Limited ranked by their cash flow conversion efficiency. Explore how high is HUTCHMED (China) Limited's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lotte Chemical Corp
KO:011170
|
-0.034x |
|
Grupo Lamosa S.A.B. de C.V
MX:LAMOSA
|
0.056x |
|
Maxvision Technology Corp
SHE:002990
|
0.031x |
|
Generate Biomedicines, Inc. Common Stock
NASDAQ:GENB
|
-0.127x |
|
Aerospace Industrial Development Corp
TW:2634
|
0.164x |
|
AG Anadolu Group Holding
IS:AGHOL
|
0.114x |
|
Chin Hin Group Bhd
KLSE:5273
|
0.088x |
|
Aarti Industries Limited
NSE:AARTIIND
|
0.094x |
Annual Cash Flow Conversion Efficiency for HUTCHMED (China) Limited (2016–2025)
The table below shows the annual cash flow conversion efficiency of HUTCHMED (China) Limited from 2016 to 2025. View H7T1 stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.25 Billion ≈ $1.46 Billion |
€-64.66 Million ≈ $-75.59 Million |
-0.052x | -8125.01% |
| 2024-12-31 | €771.85 Million ≈ $902.38 Million |
€497.00K ≈ $581.05K |
0.001x | -99.78% |
| 2023-12-31 | €743.39 Million ≈ $869.10 Million |
€219.26 Million ≈ $256.34 Million |
0.295x | +169.93% |
| 2022-12-31 | €636.87 Million ≈ $744.57 Million |
€-268.60 Million ≈ $-314.02 Million |
-0.422x | -114.67% |
| 2021-12-31 | €1.04 Billion ≈ $1.22 Billion |
€-204.22 Million ≈ $-238.76 Million |
-0.196x | -64.27% |
| 2020-12-31 | €518.95 Million ≈ $606.71 Million |
€-62.07 Million ≈ $-72.56 Million |
-0.120x | +53.75% |
| 2019-12-31 | €312.90 Million ≈ $365.82 Million |
€-80.91 Million ≈ $-94.59 Million |
-0.259x | -224.54% |
| 2018-12-31 | €412.25 Million ≈ $481.97 Million |
€-32.85 Million ≈ $-38.40 Million |
-0.080x | -332.07% |
| 2017-12-31 | €484.97 Million ≈ $566.98 Million |
€-8.94 Million ≈ $-10.46 Million |
-0.018x | +60.68% |
| 2016-12-31 | €204.06 Million ≈ $238.57 Million |
€-9.57 Million ≈ $-11.19 Million |
-0.047x | -- |
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more